VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 33.3% in November

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 800 shares, a growth of 33.3% from the October 31st total of 600 shares. Based on an average daily volume of 4,800 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of VanEck Biotech ETF

Several hedge funds have recently added to or reduced their stakes in BBH. Wilmington Savings Fund Society FSB purchased a new position in VanEck Biotech ETF in the third quarter valued at $166,000. Jane Street Group LLC increased its holdings in shares of VanEck Biotech ETF by 401.7% in the 3rd quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after acquiring an additional 6,684 shares during the last quarter. Kovitz Investment Group Partners LLC raised its position in shares of VanEck Biotech ETF by 4.6% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after acquiring an additional 141 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in VanEck Biotech ETF during the third quarter worth approximately $54,000. Finally, Truvestments Capital LLC acquired a new position in VanEck Biotech ETF in the third quarter valued at approximately $44,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ BBH opened at $167.37 on Friday. The stock’s 50-day moving average is $171.97 and its two-hundred day moving average is $173.08. VanEck Biotech ETF has a 1-year low of $150.62 and a 1-year high of $183.64.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.